IL263852B - Oligonucleotides containing modified nucleosides - Google Patents

Oligonucleotides containing modified nucleosides

Info

Publication number
IL263852B
IL263852B IL263852A IL26385218A IL263852B IL 263852 B IL263852 B IL 263852B IL 263852 A IL263852 A IL 263852A IL 26385218 A IL26385218 A IL 26385218A IL 263852 B IL263852 B IL 263852B
Authority
IL
Israel
Prior art keywords
modified nucleosides
containing modified
oligonucleotides containing
oligonucleotides
nucleosides
Prior art date
Application number
IL263852A
Other languages
Hebrew (he)
Other versions
IL263852A (en
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of IL263852A publication Critical patent/IL263852A/en
Publication of IL263852B publication Critical patent/IL263852B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/117—Modifications characterised by incorporating modified base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/205—Aptamer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
IL263852A 2016-07-01 2018-12-20 Oligonucleotides containing modified nucleosides IL263852B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662357623P 2016-07-01 2016-07-01
US201662437592P 2016-12-21 2016-12-21
PCT/US2017/040299 WO2018005974A1 (en) 2016-07-01 2017-06-30 Oligonucleotides comprising modified nucleosides

Publications (2)

Publication Number Publication Date
IL263852A IL263852A (en) 2019-01-31
IL263852B true IL263852B (en) 2022-06-01

Family

ID=59351104

Family Applications (3)

Application Number Title Priority Date Filing Date
IL291931A IL291931B2 (en) 2016-07-01 2017-06-30 Oligonucleotides comprising modified nucleosides
IL311294A IL311294A (en) 2016-07-01 2017-06-30 Oligonucleotides containing modified nucleosides
IL263852A IL263852B (en) 2016-07-01 2018-12-20 Oligonucleotides containing modified nucleosides

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL291931A IL291931B2 (en) 2016-07-01 2017-06-30 Oligonucleotides comprising modified nucleosides
IL311294A IL311294A (en) 2016-07-01 2017-06-30 Oligonucleotides containing modified nucleosides

Country Status (16)

Country Link
US (4) US10927380B2 (en)
EP (3) EP3913058B1 (en)
JP (3) JP7203613B2 (en)
KR (2) KR102501963B1 (en)
CN (2) CN109312346B (en)
AU (1) AU2017290804B2 (en)
BR (1) BR112018075869A8 (en)
DK (1) DK3478843T3 (en)
ES (2) ES2886639T3 (en)
IL (3) IL291931B2 (en)
MX (1) MX2018014771A (en)
PL (1) PL3478843T3 (en)
RU (2) RU2021137915A (en)
SG (2) SG10201911369PA (en)
TW (1) TWI770036B (en)
WO (1) WO2018005974A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10481155B2 (en) * 2018-03-09 2019-11-19 Somalogic, Inc. Proteomic assay using quantum sensors
WO2021202376A1 (en) 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
EP4204566A1 (en) * 2020-08-28 2023-07-05 Galderma Holding SA Novel x-aptamers for the use in detection of snap25
WO2023009898A1 (en) * 2021-07-30 2023-02-02 The Regents Of The University Of California Functionally-enhanced xna
EP4715063A1 (en) 2023-05-16 2026-03-25 Konica Minolta, Inc. Method for acquiring compound having molecular recognition ability, method for identifying sample, and trained model for predicting compound having molecular recognition ability
WO2025235440A1 (en) 2024-05-07 2025-11-13 Somalogic Operating Co., Inc. Nucleic acid translator gates for protein measurement
WO2026003215A1 (en) 2024-06-27 2026-01-02 Commissariat A L'energie Atomique Et Aux Energies Alternatives Bases chemically modified with a cleavable group and methods of selecting functional nucleic acids comprising same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
CA2084987C (en) 1990-06-11 2007-02-13 Gilead Sciences, Inc. Nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5719273A (en) * 1993-06-14 1998-02-17 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modifications methods using nucleophiles and carbon monoxide
US5945527A (en) * 1996-05-30 1999-08-31 Nexstar Pharmaceuticals, Inc. Palladium catalyzed nucleoside modification methods using nucleophiles and carbon monoxide
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
JP3978187B2 (en) 2002-03-19 2007-09-19 富士通株式会社 Functional molecule and production method thereof
EP2952894B1 (en) 2006-01-17 2017-08-30 Somalogic, Inc. Kits comprising aptamers
ZA200903562B (en) 2006-11-14 2010-07-28 Ribomic Inc Aptamer against midkine and use thereof
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
JP5750209B2 (en) 2007-03-16 2015-07-15 アプタ バイオサイエンス リミテッド Functional molecule, amidite for functional molecule synthesis, and target substance analysis method
MX344253B (en) 2007-07-17 2016-12-09 Somalogic Inc Method for generating aptamers with improved off-rates.
WO2009028345A1 (en) 2007-08-31 2009-03-05 Fujitsu Limited Dimer amidite for synthesis of nucleic acid, nucleic acid synthesis method
JP4499141B2 (en) 2007-09-05 2010-07-07 富士通株式会社 Modified nucleic acid synthesis amidite and modified nucleic acid synthesis method
RU2401306C2 (en) * 2008-12-17 2010-10-10 Научно-исследовательский институт Физико-химической биологии имени А.Н. Белозерского Московского Государственного Университета имени М.В. Ломоносова Aptamer oligonucleotide - direct thrombin inhibitor
US8569252B2 (en) * 2009-04-15 2013-10-29 Postech Academy-Industry Foundation Nucleolin specific aptamer and use thereof
AU2011223527B2 (en) * 2010-03-03 2014-11-13 Somalogic Operating Co., Inc. Aptamers to 4-1BB and their use in treating diseases and disorders
EP2683729B1 (en) 2011-03-10 2017-05-03 Somalogic, Inc. Aptamers for clostridium difficile diagnostics
ES2742284T3 (en) 2012-03-28 2020-02-13 Somalogic Inc Aptamers against PDGF and VEGF and their use in the treatment of conditions mediated by PDGF and VEGF
CN109439664B (en) 2013-03-14 2024-03-08 私募蛋白质体操作有限公司 Aptamer binding to IL-6 and use thereof in the treatment or diagnosis of IL-6 mediated disorders
SG11201602063UA (en) * 2013-09-24 2016-04-28 Somalogic Inc Multiaptamer target detection
RU2658363C2 (en) 2013-10-11 2018-06-21 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Aqueous herbicidal concentrates
SG10202006426QA (en) * 2013-11-21 2020-08-28 Somalogic Inc Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto
ES2764669T3 (en) * 2014-02-18 2020-06-04 Somalogic Inc Compositions and methods for the detection of microorganisms
WO2015153860A1 (en) * 2014-04-04 2015-10-08 Somalogic, Inc. Glomerular filtration rate biomarkers and uses thereof
NO2718257T3 (en) * 2014-05-30 2018-04-14
US20170335395A1 (en) * 2014-10-27 2017-11-23 The Trustees Of The University Of Pennsylvania A parkinson's disease diagnostic biomarker panel
AU2015353767B2 (en) * 2014-11-24 2021-09-09 Somalogic Operating Co., Inc. Nucleic acid compounds for binding growth differentiation factor 11

Also Published As

Publication number Publication date
RU2763470C2 (en) 2021-12-29
KR20230031972A (en) 2023-03-07
EP4520337A2 (en) 2025-03-12
JP2024147814A (en) 2024-10-16
SG11201811199QA (en) 2019-01-30
US20230313202A1 (en) 2023-10-05
MX2018014771A (en) 2019-04-25
KR102501963B1 (en) 2023-02-21
EP3913058A1 (en) 2021-11-24
CN109312346B (en) 2024-07-30
AU2017290804A1 (en) 2018-12-20
US20250129373A1 (en) 2025-04-24
JP2019527043A (en) 2019-09-26
RU2019102588A3 (en) 2020-11-30
IL263852A (en) 2019-01-31
BR112018075869A2 (en) 2019-04-02
RU2019102588A (en) 2020-08-04
KR20190024894A (en) 2019-03-08
ES3013534T3 (en) 2025-04-14
US12180482B2 (en) 2024-12-31
JP7531574B2 (en) 2024-08-09
PL3478843T3 (en) 2022-01-31
US10927380B2 (en) 2021-02-23
CN109312346A (en) 2019-02-05
IL291931A (en) 2022-06-01
JP2023036881A (en) 2023-03-14
BR112018075869A8 (en) 2022-10-18
AU2017290804B2 (en) 2024-02-15
IL291931B2 (en) 2024-08-01
CA3027626A1 (en) 2018-01-04
DK3478843T3 (en) 2021-08-30
US11578330B2 (en) 2023-02-14
EP3913058B1 (en) 2025-01-01
JP7203613B2 (en) 2023-01-13
TWI770036B (en) 2022-07-11
ES2886639T3 (en) 2021-12-20
WO2018005974A4 (en) 2018-03-22
US20190177730A1 (en) 2019-06-13
SG10201911369PA (en) 2020-01-30
US20210171951A1 (en) 2021-06-10
EP3478843A1 (en) 2019-05-08
IL291931B1 (en) 2024-04-01
IL311294A (en) 2024-05-01
CN118910063A (en) 2024-11-08
RU2021137915A (en) 2022-02-04
EP3913058C0 (en) 2025-01-01
EP4520337A3 (en) 2025-08-13
TW201803992A (en) 2018-02-01
EP3478843B1 (en) 2021-08-04
WO2018005974A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
EP3664817A4 (en) CHEMICALLY MODIFIED OLIGONUCLEOTIDES
EP3642334C0 (en) NUCLEIC ACID-GUIDED NUCLEASES
EP3408391A4 (en) BRANCHED OLIGONUCLEOTIDES
EP3307889A4 (en) DEFINED MULTI-CONJUGATED OLIGONUCLEOTIDES
IL257091B (en) Targeted oligonucleotides
DK3433368T3 (en) TRANSREPLICATING RNA
EP3464313A4 (en) 5'-CYCLO-PHOSPHONATE-MODIFIED NUCLEOTIDES
MA54568A (en) PREDETERMINED NUCLEOTIDE SUBSTITUTIONS
EP3535566C0 (en) BIOSENSOR
EP3314027A4 (en) THERAPEUTIC OLIGONUCLEOTIDES
DK3188836T3 (en) DNA SYNTHESIS
EP3286549A4 (en) BIOSENSOR
EP3156789C0 (en) BIOSENSOR
IL263852B (en) Oligonucleotides containing modified nucleosides
EP3315430A4 (en) CONTAINING
EP3388693A4 (en) CLIP
EP3409779A4 (en) MONOCATERARY OLIGONUCLEOTIDE
EP3395436A4 (en) microreactor
EP3387414A4 (en) BIOSENSOR
EP3525928A4 (en) CATALYTIC ARTICLES
EP3619311C0 (en) DNA ARRANGEMENT
EP3371575A4 (en) BIOSENSOR
EP3390240A4 (en) CARRYING STRUCTURE
DK3109141T3 (en) HOLDER
HUE043622T2 (en) holding